POET Technologies: Balancing a $400 Million Expansion With a $503,000 Revenue and a Class-Action Countdown

POET Technologies is trying to pull off a high-wire act. The company has secured a $400 million cash injection, staked a claim in the booming AI photonics market, and signed a potential $500 million customer deal. Yet its latest quarterly revenue came in at just $503,000, and a looming class-action lawsuit threatens to undermine investor confidence.

The disconnect between ambition and reality is stark. For the first quarter of 2026, POET generated $503,000 in sales — more than double the year-ago period but a pittance for a company with a multi-billion-dollar market valuation. The net loss stood at $12.3 million, and operating cash flow was negative $8.8 million. Those hard numbers have put the company’s photonics story under a microscope.

The narrative that buoyed the stock rests on a structural argument: as AI clusters grow in size, the limitations of traditional electrical interconnects become critical. Optical links, especially at speeds of 800G and beyond, are seen as the solution. POET develops photonic integrated circuits, optical engines, and light sources for hyperscale data centers and AI clusters. That thesis attracted a major order from Lumilens in May — an initial $50 million purchase of optical engines, with a cumulative volume targeted at more than $500 million over five years, provided the partnership scales as planned.

Should investors sell immediately? Or is it worth buying POET Technologies?

To finance that scale-up, POET completed a $400 million direct stock placement in May. A single institutional investor bought roughly 19 million new shares along with a warrant for the same number. The proceeds are earmarked for manufacturing capacity, research, and general operations. The company plans to roughly tenfold its wafer output and optical engine assembly capacity by 2027. It currently has 115 employees worldwide and 20,000 square feet of assembly space in Malaysia.

Yet the operational ramp is clouded by a legal overhang. Rosen Law Firm is searching for a lead plaintiff in a class-action suit until June 29. The suit covers the period from April 1 to April 27, 2026, and alleges that POET made misleading statements about its U.S. tax status. A manager’s public comments are said to have violated a business agreement. Investors are seeking damages for share-price losses suffered during that window.

The stock’s journey reflects the push-pull between promise and peril. At Friday’s close of €8.26, the shares had lost 22% over the previous seven days and were trading more than 56% below the 52-week high reached on May 15. They also sat more than 20% under the 50-day moving average of €10.40. But the longer-term picture tells a different story: the stock is still up roughly 35% year-to-date and 87% from a year ago, and it remains comfortably above the 200-day average of €6.68. The annualized volatility is a staggering 128%.

The company has taken steps to avoid future tax complications by moving its headquarters to the United States. But the immediate focus for investors is whether the Lumilens order — and other potential clients — will translate into actual delivered and billed products. The production ramp through the end of 2026 will be the key test of whether POET can cross the chasm from photonics promise to serial production. Until then, the combination of a tiny revenue base, a huge cash pile, and an unresolved lawsuit will keep the stock on a roller-coaster ride.

Ad

POET Technologies Stock: New Analysis - 29 June

Fresh POET Technologies information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated POET Technologies analysis...

en | CA73044W3021 | POET | boerse | 69650326 |